公开(公告)号：US20220296612A1

公开(公告)日：2022-09-22

申请号：US17519119

申请日：2021-11-04

Applicant: Civitas Therapeutics, Inc.

Inventor： Charles D. Blizzard ,  Michael M. Lipp ,  Kevin L. Ward ,  Rachel Ryznal ,  Daniel LeBlanc ,  Mark A. Tracy ,  Rebecca Martin

IPC: A61K31/58 ,  A61K9/00 ,  A61K9/16 ,  A61K45/06 ,  A61K31/13 ,  A61K47/36 ,  A61K38/29

Abstract: The present invention provides improved pharmaceutical formulations for pulmonary delivery having improved chemical and physical stability of the therapeutic, prophylactic or diagnostic agent as compared to formulations known in the art. The improved pharmaceutical formulations of the invention for administration to the respiratory system of a patient for the treatment of a variety of disease conditions comprise a mass of biocompatible particles comprising an active agent, and a hydrogenated starch hydrosylate (HSH). The improvement over the prior art comprises the presence of HSH in the pharmaceutical formulation. The invention further relates to a method of treating diseases comprising administering the pharmaceutical formulations of the present invention to the respiratory system of a patient in need of treatment.

公开(公告)号：USD752204S1

公开(公告)日：2016-03-22

申请号：US29484448

申请日：2014-03-10

Applicant: Civitas Therapeutics, Inc.

Designer： Sean Plunkett ,  Jake P. Ganem ,  Scott E. Ganem

公开(公告)号：US09155699B2

公开(公告)日：2015-10-13

申请号：US14055959

申请日：2013-10-17

Applicant: Civitas Therapeutics, Inc.

Inventor： Blair C. Jackson ,  David J. Bennett ,  Raymond T. Bartus ,  Dwaine F. Emerich

IPC: A61K9/14 ,  A61K9/68 ,  A61K31/24 ,  A61K31/135 ,  A01N37/44 ,  A61K9/00 ,  A61K9/16 ,  A61K31/137 ,  A61K31/198 ,  A61K31/70

CPC classification number: A61K31/198 ,  A61K9/0073 ,  A61K9/0075 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1623 ,  A61K31/137 ,  A61K31/70

Abstract: In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung.

Abstract translation: 在一个方面，本发明涉及一种治疗帕金森病患者的方法，所述方法包括给患者颗粒施用包括大于约90重量百分比（wt％）的左旋多巴的患者的呼吸道。 颗粒被递送到患者的肺部系统，优选地输送到肺泡或深肺。

公开(公告)号：US20140220119A1

公开(公告)日：2014-08-07

申请号：US14174179

申请日：2014-02-06

Applicant: Civitas Therapeutics, Inc.

Inventor： Kevin D. Kee ,  Ernest D. Penachio ,  Abhijit Kamerhar ,  Michael M. Lipp ,  Richard P. Batycky

IPC: A61K9/48 ,  A61K31/198

CPC classification number: A61K9/4858 ,  A61K9/0073 ,  A61K9/0075 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/4808 ,  A61K9/4816 ,  A61K9/485 ,  A61K31/198

Abstract: The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.

Abstract translation: 本发明提供了含有可吸入粉末组合物的胶囊，其中组合物包含约75重量％或更多的左旋多巴，二棕榈酰磷脂酰胆碱（DPPC）和以小于约100g / L的工作密度为特征的盐。 本发明还提供一种含有可吸入粉末组合物的胶囊，其中所述组合物包含约75重量％或更多的左旋多巴，二棕榈酰磷脂酰胆碱（DPPC）和以小于约100g / L的工作密度为特征的盐，其中胶囊材料包含羟丙基甲基纤维素 （HPMC）和二氧化钛。

公开(公告)号：US20140150787A1

公开(公告)日：2014-06-05

申请号：US13719598

申请日：2012-12-19

Applicant: CIVITAS THERAPEUTICS, INC.

Inventor： Colleen Ellwanger ,  Brian Noble ,  Tim Coker ,  Sean Plunkett

IPC: A61M15/00

Abstract: A device for puncturing a capsule to release a powdered medicament therefrom includes a chamber for receiving the capsule. The capsule includes opposing domes and a cylindrical wall portion defined by a capsule wall radius r. The device further includes a mechanism for puncturing at least one hole in at least one dome. A center of each hole is located within an annular puncture region situated at no less than 0.4 r, and a total surface area of all puncture holes is between about 0.5% and about 2.2% of a total surface area of the capsule. The annular puncture region may, for example, be situated between about 0.4 r and about 0.8 r, or between about 0.4 r and about 0.6 r.

Abstract translation: 用于刺穿胶囊以释放粉末状药物的装置包括用于接收胶囊的腔室。 胶囊包括相对的圆顶和由胶囊壁半径r限定的圆柱形壁部分。 该装置还包括用于刺穿至少一个穹顶中的至少一个孔的机构。 每个孔的中心位于不小于0.4r的环形穿刺区域内，并且所有穿刺孔的总表面积在胶囊的总表面积的约0.5％至约2.2％之间。 环形穿刺区域可以例如位于约0.4r至约0.8r之间，或约0.4r至约0.6r之间。

公开(公告)号：US20130253065A1

公开(公告)日：2013-09-26

申请号：US13787026

申请日：2013-03-06

Applicant: CIVITAS THERAPEUTICS, INC.

Inventor： Richard P. Batycky ,  Giovanni Caponetti ,  Mariko Childs ,  Elliot Ehrich ,  Karen Fu ,  Jeffrey S. Hrkach ,  Wen-I Li ,  Michael M. Lipp ,  Mei-Ling Pan ,  Jason Summa

IPC: A61K9/00 ,  A61K31/137

CPC classification number: A61K31/137 ,  A61K9/0073 ,  A61K9/0075 ,  A61K9/1617 ,  A61K31/135 ,  A61M15/0091 ,  A61M2202/06

Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.

公开(公告)号：US20120111325A1

公开(公告)日：2012-05-10

申请号：US13096475

申请日：2011-04-28

Applicant: Jeffrey S. Hrkach

Inventor： Jeffrey S. Hrkach

IPC: A61M15/00

CPC classification number: A61M15/0091 ,  A61K9/0075 ,  A61M15/0021 ,  A61M15/0028 ,  A61M15/0035 ,  A61M15/0041 ,  A61M15/0086 ,  A61M15/08 ,  A61M2202/064 ,  A61M2206/16 ,  A61M2209/02

Abstract: The invention relates to a method of delivering an agent to the pulmonary system of a compromised patient, in a single breath-activated step, comprising administering a particle mass comprising an agent from an inhaler containing less than 5 milligrams of the mass, wherein at least about 50% of the mass in the receptacle is delivered to the pulmonary system of a patient. The invention also relates to receptacles containing the particle mass and the inhaler for use therein.

Abstract translation: 本发明涉及一种在单次呼吸激活步骤中将药剂递送至受损患者的肺系统的方法，包括从含有少于5毫克质量的吸入器施用包含药剂的颗粒物质，其中至少 容器中约50％的质量被输送到患者的肺部系统。 本发明还涉及包含用于其中的颗粒物质和吸入器的容器。

公开(公告)号：US20240198020A1

公开(公告)日：2024-06-20

申请号：US18362449

申请日：2023-07-31

Applicant: Civitas Therapeutics, Inc.

Inventor： Colleen Ellwanger ,  Brian Noble ,  Tim Coker ,  Sean Plunkett

IPC: A61M15/00

CPC classification number: A61M15/0028 ,  A61M15/0035 ,  A61M15/0041 ,  A61M2202/064

Abstract: A device for puncturing a capsule to release a powdered medicament therefrom includes a chamber for receiving the capsule. The capsule includes opposing domes and a cylindrical wall portion defined by a capsule wall radius r. The device further includes a mechanism for puncturing at least one hole in at least one dome. A center of each hole is located within an annular puncture region situated at no less than 0.4 r, and a total surface area of all puncture holes is between about 0.5% and about 2.2% of a total surface area of the capsule. The annular puncture region may, for example, be situated between about 0.4 r and about 0.8 r, or between about 0.4 r and about 0.6 r.

公开(公告)号：US20240016823A1

公开(公告)日：2024-01-18

申请号：US17892436

申请日：2022-08-22

Applicant: Civitas Therapeutics, Inc.

Inventor： Michael M. Lipp ,  Abhijit Kamerkar ,  Fahad Gilani ,  Holly Chan ,  Michael Tauber

IPC: A61K31/685 ,  A61K9/00 ,  A61K9/14 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  A61K47/36 ,  A61K47/42 ,  C07K14/785

CPC classification number: A61K31/685 ,  A61K9/0075 ,  A61K9/14 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/183 ,  A61K47/26 ,  A61K47/36 ,  A61K47/42 ,  C07K14/785 ,  A61K38/00

Abstract: The present invention is directed respirable, dry powder particle formulations of lung surfactants that optionally comprise surfactant proteins and that are formulated for delivery to the pulmonary system via inhalation.

公开(公告)号：US20220296559A1

公开(公告)日：2022-09-22

申请号：US17517157

申请日：2021-11-02

Applicant: Civitas Therapeutics, Inc.

Inventor： Kevin L. Ward ,  Thean Y. Yeoh ,  Rebecca Martin ,  Charles D. Blizzard

IPC: A61K31/351 ,  A61K9/00 ,  A61K9/16 ,  A61K31/196

Abstract: The present invention is related to pharmaceutical formulations and methods of treating a subject afflicted with the influenza virus, the method includes administering to the respiratory tract of the patient particles that include more than about 5% to about 50% weight percent (wt %) of a neuraminidase inhibitor. The particles are delivered to the patient's pulmonary system, including the upper airways, central airways and deep lung.